Trastuzumab emtansine

Phase 3Antibody–drug conjugate

SSeoul National University Bundang Hospital

Trastuzumab emtansine is one of 59 therapeutic programs targeting Metastatic Salivary Gland Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Salivary Gland CarcinomaRecruiting

Metastatic Breast CancerRecruiting

Advanced LymphomaActive, not recruiting

Anatomic Stage II Breast Cancer AJCC V8Active, not recruiting

HER2-Positive Metastatic Breast CancerRecruiting

Primary Breast CancerActive, not recruiting

Metastatic Salivary Gland CarcinomaPhase 2

Recruiting

Metastatic Breast CancerPreclinical

Recruiting

Advanced LymphomaPhase 2

Active, not recruiting

Anatomic Stage II Breast Cancer AJCC V8Phase 2

Active, not recruiting

HER2-Positive Metastatic Breast CancerPhase 2

Recruiting

Primary Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Advanced Lymphoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Phase 2

2 2

Perjeta

Roche

Phase 2

1 3

Opdualag

Bristol-Myers Squibb

Phase 2

1 4

Mekinist

Novartis

Phase 2

1 5

Erivedge

Roche

Phase 2

1 6

Vitrakvi

Bayer

Phase 2

1 7

Adavosertib

AstraZeneca

Phase 2

1 8

Mektovi

Pfizer

Phase 2

1 9

Truqap

AstraZeneca

Phase 2

1 10

Aliqopa

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Advanced Lymphoma

NCT02465060

Q1 2027

Recruiting

Solid Tumor

NCT05525858

Q3 2028

Phase 2Recruiting

Metastatic Salivary Gland Carcinoma

NCT05408845

Q1 2029

PreclinicalRecruiting

Metastatic Breast Cancer

NCT06324357

Clinical

Trials by Indication[1]

Anatomic Stage II Breast Cancer AJCC v81 trial

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04266249·2,175 enrolled

Advanced Lymphoma1 trial

Molecular Analysis for Therapy Choice (MATCH)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02465060·6,452 enrolled

Metastatic Breast Cancer1 trial

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Preclinical·NCT06324357·768 enrolled

HER2-positive Metastatic Breast Cancer1 trial

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

Recruiting·JJules Bordet Institute·Phase 2·NCT06595563·87 enrolled

Primary Breast Cancer1 trial

A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT06126640·1,615 enrolled

2 more indications

Metastatic Salivary Gland Carcinoma1 trial

A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Recruiting·NNRG Oncology·Phase 2·NCT05408845·146 enrolled

Solid Tumor1 trial

KOrean Precision Medicine Networking Group Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Recruiting·SSeoul National University Bundang Hospital··NCT05525858·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Trastuzumab emtansine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Trastuzumab emtansine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Seoul National University Bundang Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate
Highest Phase: Phase 3[1]
Company: SSeoul National University Bundang Hospital

Trastuzumab emtansine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2028

Q1 2029

Trials by Indication[1]

Anatomic Stage II Breast Cancer AJCC v81 trial

Advanced Lymphoma1 trial

Metastatic Breast Cancer1 trial

HER2-positive Metastatic Breast Cancer1 trial

Primary Breast Cancer1 trial

Metastatic Salivary Gland Carcinoma1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News